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Previewsenvironment where few effective treat-
ment strategies short of bariatric sur-
gery are available to help obese patients.
It is clear that more creative strategies
from a wider range of disciplines are
needed. To that end, further under-
standing of how adipose tissue signal-
ing is altered by various aspects of its
milieu, including the supporting blood
vessels, macrophages, and its extracel-
lular matrix, is necessary if we are to bring
more therapies to the large unmetmedical2 Cell Metabolism 15, January 4, 2012 ª2012need presented by increasing rates of
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While age-dependent stem cell decline is widely recognized as being a key component of organismal aging,
the underlying mechanisms remain elusive. In this issue of Cell Metabolism, Suomalainen and colleagues
provide evidence that mitochondrial mutation and associated reactive oxygen species can adversely impact
tissue-specific stem and progenitor cell function.Physiological aging invariably leads to
a loss in normal tissue maintenance and
reduced regenerative potential. The fact
that these processes are normally under
the functional purview of adult tissue-
specific stem cells implicates age-associ-
ated stem cell decline as a fundamental
contributor to the aging of tissues and
organisms. Indeed, the importance of
the stem cell compartment in contributing
to age-associated pathophysiology has
been demonstrated in a number of stud-
ies (Rossi et al., 2008). Consistent with
the inherent complexity of physiological
aging, the mechanistic basis for age-
related stem cell decline is similarly
complex, with evidence suggesting the
involvement of cellular, genetic, and epi-
genetic components (Rossi et al., 2008).
However, recent evidence from a number
of papers, including a paper by Suomalai-
nen and colleagues in this issue of CellMetabolism, suggests that accumulating
mitochondrial DNA damage may also be
an important contributor to somatic stem
cell decline with age.
Mitochondria are frequently referred
to as the cell’s ‘‘power plants’’ since
they play a fundamental role in the
production of adenosine triphosphate
(ATP) through oxidative phosphorylation
(OXPHOS). Most aerobic organisms use
some form of OXPHOS because it is
a highly efficient method for produc-
ing ATP; however, the downside of this
energy-producing pathway is that it also
leads to the production of reactive oxygen
species (ROS) that have the potential to
damage cellular macromolecules and, in
such a way, contribute to aging. Mito-
chondrial DNA (mtDNA) is believed to be
highly susceptible to oxidative damage
in part because of its proximity to the elec-
tron transport chain, but also becausemtDNA lacks protective histones. Accu-
mulation of damage in the mitochondrial
genome has been proposed to lead to
mitochondrial dysfunction and concomi-
tant cellular decline and, in such a way,
contribute to physiological aging (Har-
man, 1972). This long-held theory was
supported experimentally with the gener-
ation of mtDNA ‘‘mutator’’ mice bearing a
proofreading-deficient mtDNA polymer-
ase (POLG) that exhibit a spectrum of
degenerative phenotypes reminiscent of
aging (Kujoth et al., 2005; Trifunovic
et al., 2004). More recently, these mice
have also provided the necessary ex-
perimental tool to address how mtDNA
mutation accumulation impacts stem cell
function and to determine whether it
contributes to age-associated stem cell
decline.
Within mammalian tissues, aging has
been most comprehensively studied in
Cell Metabolism
Previewsthe hematopoietic system and, to a lesser
extent, the brain. In the blood, the hema-
topoietic stem cell (HSC) compartment
has been well documented to contribute
to pathophysiological conditions associ-
ated with aging, which include reduced
regenerative potential, diminished adap-
tive immune competence, and myeloge-
nous disease predisposition (Rossi et al.,
2008). And while genomic DNA damage
accrual is thought to limit the regenerative
response of HSCs from old mice (Rossi
et al., 2007), the impact of mitochondrial
mutagenesis on hematopoietic aging has
until recently been unexplored. Two
groups have recently shown that the
mtDNA mutator mice exhibited a number
of hematopoietic phenotypes, including
abnormalities in erythroid and lymphocyte
development (Chen et al., 2009; Norddahl
et al., 2011). The fact that these hemato-
logic deficiencies could be transplanted
into wild-type recipients indicated that
they were cell-autonomous defects trans-
mitted by HSCs (Chen et al., 2009; Nord-
dahl et al., 2011). However, although
anemia and lymphoid deficiencies are
commonly associated with aging in both
mice and people, Bryder and colleagues
went on to show that the aging of muta-
tor stem cells was molecularly distinct
from normal physiological stem cell aging
(Norddahl et al., 2011). Using a tran-
scriptional profiling strategy to compare
steady-state mutator HSCs against stem
cells purified from old wild-typemice, little
similarity was noted in their respective
profiles, suggesting that, at least at this
resolution, mitochondrial mutation-driven
stem cell decline could be uncoupled
from normal physiological stem cell aging
(Norddahl et al., 2011). Nonetheless, it re-
mains possible that mitochondrial muta-
tion contributes mechanistically to stem
cell aging despite the lack of evidence
at the transcriptional level, perhaps by
influencing the mobilization of energy
stores that these normally dormant stem
cells must harness when called into
action under conditions of stress or
regeneration.
An important outstanding question was
whether the hematopoietic phenotypes
exhibited by the mutator mice arose onlyafter a threshold level of mtDNA mutation
had occurred in the adult animals as they
aged. This is one of several issues ad-
dressed in a new article by Suomalainen
and colleagues featured in this issue
(Ahlqvist et al., 2012). To examine the
timing of the mutator hematopoietic de-
fect manifestation, the investigators ex-
amined embryonic hematopoietic devel-
opment at E13.5–15.5 in the fetal liver of
mutator fetuses and discovered dimin-
ished erythropoiesis and reduced fre-
quencies of erythroid progenitors, likely
representing a precursor phenotype to
the later-observed adult anemia (Chen
et al., 2009; Norddahl et al., 2011). They
also observed a defect in fetal lymphopoi-
esis characterized by elevated B220-
positive B cells. Importantly, they discov-
ered that administration of the antioxidant
N-acetylcysteine (NAC) throughout preg-
nancy could normalize fetal hematopoi-
esis to wild-type levels, implicating ROS
as an underlying mediator leading to the
fetal hematopoietic phenotypes observed
in the mutator mice. The researchers also
questioned how other tissue-specific
stem cell populations might be affected
in the mutator mice. In the brain, the
numbers of stem cells in the subventricu-
lar zone (SVZ) are the result of a tightly
controlled balance between the cell fates
of self-renewal, differentiation, and apo-
ptosis. This means that controlling of the
fate of SVZ NSCs, which can be identified
by their nestin positivity, plays a critical
role in determining the number of neu-
rons, astrocytes, and oligodendrocytes
in the brain. The researchers therefore
examined the number of nestin-positive
neural cells in the SVZ of wild-type and
mutator mice and discovered a significant
decrease in this important cell type in the
mutants. Despite the observed decrease
in NSCs, however, a multiparameter his-
tological and biochemical examination
failed to uncover significant in vivo neuro-
logic phenotypes in aged mutator mice.
However, when the authors examined
the NSCs using an in vitro neurosphere
self-renewal assay, they discovered that
mutator NSCs formed significantly fewer
neurospheres than wild-type cells, indi-
cating that these cells suffer from a defectCell Metabolismin self-renewal that could explain the de-
creased NSC numbers observed in vivo.
Importantly, as the authors had observed
with the hematopoietic defects, the self-
renewal deficits of the mutator NSCs
could also be largely ameliorated through
treatment with NAC.
The findings of Suomalainen and col-
leagues at once support a growing body
of evidence showing how critical ROS
management is for proper stem and pro-
genitor cell function (Ito et al., 2006; To-
thova and Gilliland, 2007) and, at the
same time, identify that a consequence
of mutation accrual in the mitochondrial
genome is deregulation of ROS, which
can then work its mischief by impairing
tissue-specific stem and progenitor cells.
However, the connection of mitochondrial
genome maintenance to physiological
stem cell aging remains unclear.REFERENCES
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